Higher Binding Affinity and <i>in vitro</i> Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab.

Liddament, Mark; Husten, Jean; Estephan, Tanya; Laine, David; Mabon, David; Pukac, Laurie; Lyons, Jacquelyn; Clarke, Adam W; Doyle, Anthony

Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab.

Liddament, Mark; Husten, Jean; Estephan, Tanya; Laine, David; Mabon, David; Pukac, Laurie; Lyons, Jacquelyn; Clarke, Adam W; Doyle, Anthony.

Afiliación

Liddament M; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia. mark.liddament@tevapharm.com.
Husten J; R&D, Biologics, Teva Pharmaceuticals USA, West Chester, PA, USA.
Estephan T; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia. mark.liddament@tevapharm.com.
Laine D; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia.
Mabon D; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia.
Pukac L; R&D, Biologics, Teva Pharmaceuticals USA, West Chester, PA, USA.
Lyons J; R&D, Biologics, Teva Pharmaceuticals USA, West Chester, PA, USA.
Clarke AW; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia.
Doyle A; R&D, Biologics Lead Antibody Discovery, Teva Pharmaceuticals Australia, Sydney, NSW, Australia.

Allergy Asthma Immunol Res ; 11(2): 291-298, 2019 Mar.

Article en En | MEDLINE | ID: mdl-30661320

Palabras clave

Reslizumab; antibody affinity; drug evaluation, preclinical; interleukin-5; mepolizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Allergy Asthma Immunol Res Año: 2019 Tipo del documento: Article País de afiliación: Australia